Hironaka Junya, Ushigome Emi, Kondo Yuriko, Hashimoto Yoshitaka, Osaka Takafumi, Majima Saori, Nakanishi Naoko, Okada Hiroshi, Senmaru Takafumi, Hamaguchi Masahide, Yamazaki Masahiro, Fukui Michiaki
Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Department of Diabetology, Kameoka Municipal Hospital, Kyoto, Japan.
Diab Vasc Dis Res. 2025 Jan-Feb;22(1):14791641251318309. doi: 10.1177/14791641251318309.
This study aimed to investigate the effects of oral semaglutide on the changes in food preference of Japanese patients with type 2 diabetes.
This retrospective multicenter study included 75 patients with type 2 diabetes who received oral semaglutide. The primary outcome was the change in the score of brief-type self-administered diet history questionnaire (BDHQ) score 3 months after the initiation of oral semaglutide treatment. The secondary outcome was the change in the Control of Eating Questionnaire (CoEQ), HbA1c, and body mass index (BMI) after 3 months.
The median age, BMI, and HbA1c of the 23 participants were 64.0 years, 26.9 kg/m, and 7.6% (59 mmol/mol). The BDHQ results showed total energy was significantly reduced. Among the individual nutrients, carbohydrates most decreased. The CoEQ results particularly showed declines in cravings for something sweet, chocolate or chocolate flavored foods, and starchy foods, satisfaction at meals, frequency and intensity of food craving, difficulty of resisting the craving for food, and frequency of eating in response to cravings for food were significantly lower after 3 months. The mean HbA1c and BMI significantly decreased.
In Japanese patients with type 2 diabetes, oral semaglutide treatment decreased total energy intake and changed food preferences.
本研究旨在调查口服司美格鲁肽对日本2型糖尿病患者食物偏好变化的影响。
这项回顾性多中心研究纳入了75例接受口服司美格鲁肽治疗的2型糖尿病患者。主要结局是口服司美格鲁肽治疗开始3个月后简易自填式饮食史问卷（BDHQ）得分的变化。次要结局是3个月后饮食控制问卷（CoEQ）、糖化血红蛋白（HbA1c）和体重指数（BMI）的变化。
23名参与者的年龄中位数、BMI和HbA1c分别为64.0岁、26.9kg/m²和7.6%（59mmol/mol）。BDHQ结果显示总能量显著降低。在单一营养素中，碳水化合物减少最多。CoEQ结果特别显示，3个月后，对甜食、巧克力或巧克力味食物以及淀粉类食物的渴望、进餐满意度、食物渴望的频率和强度、抵抗食物渴望的难度以及因食物渴望而进食的频率均显著降低。平均HbA1c和BMI显著下降。
在日本2型糖尿病患者中，口服司美格鲁肽治疗可降低总能量摄入并改变食物偏好。
